Trazodone 50 mg Tablets — Generic For Desyrel — Zydus

These highlights do not include all the information needed to use TRAZODONE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for TRAZODONE HYDROCHLORIDE TABLETS.

TRAZODONE HYDROCHLORIDE tablets, for oral use

Initial U.S. Approval: 1981

WARNING: SUICIDAL THOUGHTS and BEHAVIORS

See full prescribing information for complete boxed warning.

Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients (5.1)

Closely monitor for clinical worsening and emergence of suicidal thoughts and behaviors (5.1)

Trazodone is not approved for use in pediatric patients (8.4)

Indications And Usage

Trazodone is a selective serotonin reuptake inhibitor indicated for the treatment of major depressive disorder (MDD) (1).

Dosage And Administration

Starting dose: 150 mg in divided doses daily. May be increased by 50 mg per day every three to four days. Maximum dose: 400 mg per day in divided doses (2).

Trazodone hydrochloride tablets should be taken shortly after a meal or light snack (2).

Tablets should be swallowed whole or broken in half along the score line, and should not be chewed or crushed (2).

When discontinued, gradual dose reduction is recommended (2).

Dosage Forms And Strengths

Scored tablets of 50 mg, 100 mg, 150 mg and 300 mg (3).

Contraindications

Concomitant use of monoamine oxidase inhibitors (MAOIs), or use within 14 days of stopping MAOIs (4).

Warnings And Precautions

• Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. If it occurs, discontinue trazodone and initiate supportive treatment (5.2).
• Cardiac Arrhythmias: Increases the QT interval. Avoid use with drugs that also increase the QT interval and in patients with risk factors for prolonged QT interval (5.3)
• Orthostatic Hypotension and Syncope: Warn patients of risk and symptoms of hypotension (5.4).
• Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk (5.5).
• Priapism: Cases of painful and prolonged penile erections and priapism have been reported. Immediate medical attention should be sought if signs and symptoms of prolonged penile erections or priapism are observed (5.6).
• Activation of Mania or Hypomania: Screen for bipolar disorder and monitor for mania or hypomania (5.7).
• Potential for Cognitive and Motor Impairment: Has potential to impair judgment, thinking, and motor skills. Advise patients to use caution when operating machinery (5.9).
• Angle-Closure Glaucoma: Avoid use of antidepressants, including trazodone, in patients with untreated anatomically narrow angles. (5.10).

• Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. If it occurs, discontinue trazodone and initiate supportive treatment (5.2).
• Cardiac Arrhythmias: Increases the QT interval. Avoid use with drugs that also increase the QT interval and in patients with risk factors for prolonged QT interval (5.3)
• Orthostatic Hypotension and Syncope: Warn patients of risk and symptoms of hypotension (5.4).
• Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk (5.5).
• Priapism: Cases of painful and prolonged penile erections and priapism have been reported. Immediate medical attention should be sought if signs and symptoms of prolonged penile erections or priapism are observed (5.6).
• Activation of Mania or Hypomania: Screen for bipolar disorder and monitor for mania or hypomania (5.7).
• Potential for Cognitive and Motor Impairment: Has potential to impair judgment, thinking, and motor skills. Advise patients to use caution when operating machinery (5.9).
• Angle-Closure Glaucoma: Avoid use of antidepressants, including trazodone, in patients with untreated anatomically narrow angles. (5.10).

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. If it occurs, discontinue trazodone and initiate supportive treatment (5.2).

Cardiac Arrhythmias: Increases the QT interval. Avoid use with drugs that also increase the QT interval and in patients with risk factors for prolonged QT interval (5.3)

Orthostatic Hypotension and Syncope: Warn patients of risk and symptoms of hypotension (5.4).

Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk (5.5).

Priapism: Cases of painful and prolonged penile erections and priapism have been reported. Immediate medical attention should be sought if signs and symptoms of prolonged penile erections or priapism are observed (5.6).

Activation of Mania or Hypomania: Screen for bipolar disorder and monitor for mania or hypomania (5.7).

Potential for Cognitive and Motor Impairment: Has potential to impair judgment, thinking, and motor skills. Advise patients to use caution when operating machinery (5.9).

Angle-Closure Glaucoma: Avoid use of antidepressants, including trazodone, in patients with untreated anatomically narrow angles. (5.10).

Adverse Reactions

Most common adverse reactions (incidence ≥ 5% and twice that of placebo) are: edema, blurred vision, syncope, drowsiness, fatigue, diarrhea, nasal congestion, weight loss (6).

To report SUSPECTED ADVERSE REACTIONS, contact Zydus Pharmaceuticals (USA) Inc. at 1-877-993-8779 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Drug Interactions

CNS Depressants: Trazodone may enhance effects of alcohol, barbiturates, or other CNS depressants (7).

CYP3A4 Inhibitors: Consider trazodone dose reduction based on tolerability (2.5, 7).

CYP3A4 Inducers: Increase in trazodone dosage may be necessary (2.5, 7).

Digoxin or Phenytoin: Monitor for increased digoxin or phenytoin serum levels (7).

Warfarin: Monitor for increased or decreased prothrombin time (7).

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 1/2026